Outlook Therapeutics Stock Plunges After FDA Rejects Eye Drug for Third Time
Outlook Therapeutics (OTLK) shares crashed 63% after FDA rejected its wet AMD treatment ONS-5010/Lytenava again, requesting more efficacy evidence without specifying requirements.
